Astellas
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 1 | ×1.50 | 3 |
| preclinical | ×1.50 | 3 |
Strategy profile
Based on 14 disclosed transactions, Astellas concentrates its licensing activity in Ophthalmology, Oncology, and Codev Deals. Astellas pays a 1.50x premium over market median. Their most common deal structure is License, with an average disclosed value of $2.1B. Most recent activity: 2026.
Pipeline coverage & gaps
Astellas has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 5 | $124M | $1.2B |
| Collaboration | 4 | $182M | $1.6B |
| Acquisition | 4 | $3.9B | $3.9B |
| Option | 1 | $50M | $2.2B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | — | CytomX Therapeutics | solid tumors | preclinical | $80M | $1.7B |
| 2026 | VIR-5500 | Vir Biotechnology | prostate cancer | phase_1 | $335M | $1.7B |
| 2025 | XNW-27011 | Evopoint | CLDN18.2-positive cancers | unknown | $130M | $1.3B |
| 2025 | CLDN18.2 ADC | Evopoint Biosciences | — | unknown | — | $1.5B |
| 2025 | CLDN18.2 ADC | Evopoint | oncology | unknown | — | $1.5B |
| 2024 | STAC-BBB capsid (neuro gene therapy) | Sangamo Therapeutics | Undisclosed neurological diseases | preclinical | $20M | $1.3B |
| 2024 | atopicderm | Connect Biopharma | atopicderm | phase_2 | $25M | $350M |
| 2023 | cardiomyopathy | BridgeBio Pharma | cardiomyopathy | phase_3 | $400M | $1.7B |
| 2023 | frontotemporal dementia | AviadoBio | frontotemporal dementia | phase_1 | $50M | $2.2B |
| 2023 | R100 vector (rare ophtho GT) | 4D Molecular Therapeutics | Rare retinal diseases | preclinical | $50M | $963M |
| 2023 | dryAmdGA | Iveric Bio | dryAmdGA | approved | $5.9B | $5.9B |
| 2023 | geographic_atrophy | Iveric Bio | geographic_atrophy | approved | $5.9B | $5.9B |
| 2020 | Veozah (fezolinetant) | Ogeda | Hot Flashes/Vasomotor Symptoms | phase_2 | $800M | $800M |
| 2019 | AT132 (X-linked myotubular myopathy gene therapy) | Audentes Therapeutics | X-Linked Myotubular Myopathy | phase_1 | $3.0B | $3.0B |
How this is computed
For each Astellas deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 9 disclosed deal premiums vs. peer medians. Raw premium 1.784, clamped to [0.7, 1.5].